While HP among patients with either no or few bone metastases remained stable, there was a significant mean decrease of all three HP from baseline to restaging among patients with disseminated or diffuse bone involvement, which inversely correlated with the change in PSA and tumour volume on PSMA PET at restaging, respectively. This evidence concerns the gene KLK3 and neoplasm.